You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 1
  • Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer

Article Text

Article menu

Download PDFPDF

Poster Presentation
Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer
  1. Joseph Baar1,
  2. Walter J Storkus2,
  3. James Finke3,
  4. Lisa Butterfield2,
  5. Hillard Lazarus1,
  6. Jane Reese1,
  7. Katharine Downes1,
  8. Thomas Budd3,
  9. Adam Brufsky2 and
  10. Pingfu Fu1
  1. Aff1 Seidman Cancer Center Cleveland, Ohio USA
  2. Aff2 grid.21925.3d0000000419369000University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania USA
  3. Aff3 grid.239578.20000000106754725Taussig Cancer Center Cleveland, Ohio USA

https://doi.org/10.1186/2051-1426-3-S1-P3

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Cancer vaccines based on tumor-associated antigens are rarely curative in advanced cancer. This limitation relates to the heterogeneity of cancer due to defects in antigen presentation and altered immunophenotypes. Therefore, another method to promote anti-tumor immunity is to prime T cells against tumor-associated stromal cells. We have reported [1] that IL-12 gene therapy of established HLA-A2neg B16 melanomas in HLA-A2+ transgenic mice resulted in CD8+ T cell-mediated immunity against the host HLA-A2+ stromal cells within the tumor microenvironment (TME). We have also shown [2] that vaccines based on a subset of tumor blood vessel antigen (TBVA)-derived peptides (DLK1, EphA2, HBB, NRP1, PDGFRβ, RGS5 or TEM1) prevented HLA-A2neg MC38 tumor establishment and promoted the regression of tumors in HLA-A2+ mice by CD8+ T cell targeting of HLA-A2+ pericytes and vascular endothelial cells in the TME. Based on this pre-clinical data, we propose to undertake a Susan G. Komen -funded (IIR13261822) clinical trial of chemo-immunotherapy using the immunomodulatory drug gemcitabine with a dendritic cell vaccine pulsed with six HLA-A2-presented TBVA-derived peptides (DLK1310-318, EphA2883-891, HBB31-39, NRP1433-441, RGS55-13 and TEM1691-700) in 30 HLA-A2+ patients with metastatic breast cancer. The specific aims of this study are to determine vaccine-induced generation of TBVA-Tc1 immunity and clinical response.

    References

    1. 1.↵
      1. Zhao X,
      2. Bose A,
      3. Komita H,
      4. Taylor JL,
      5. Kawabe M,
      6. Chi N,
      7. Spokas L,
      8. Lowe DB,
      9. Goldbach C,
      10. Alber S,
      11. Watkins SC,
      12. Butterfield LH,
      13. Kalinski P,
      14. Kirkwood JM,
      15. Storkus WJ
      . Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Mol Ther. 2011;19:4805–14. pmcid:3070096 doi:10.1038/mt.2010.295
      OpenUrlCrossRefPubMed
    2. 2.↵
      1. Zhao X,
      2. Bose A,
      3. Komita H,
      4. Taylor JL,
      5. Chi N,
      6. Lowe DB,
      7. Okada H,
      8. Cao Y,
      9. Mukhopadhyay D,
      10. Cohen PA,
      11. Storkus WJ
      . Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol. 2012;188:1782–8. pmcid:3273624 doi:10.4049/jimmunol.1101644
      OpenUrlAbstract/FREE Full Text